HHS Sends Its Peptide Compounding Plan to the White House

For the first time, the plan to let pharmacies compound peptides like BPC-157 has left the realm of anonymous sourcing and landed on a dated federal record: on October 15, the Department of Health and Human Services filed a peptide "interim access policy" with the White House Office of Management and Budget for review, according to a government posting reported by the Associated Press.

From anonymous sourcing to a paper trail

The Journal covered this plan when it was still a drafting-stage rumor: on October 7-8, the Washington Post reported, via two unnamed officials, that HHS and the FDA were drafting a policy of "interim enforcement discretion" for peptide compounding. A week later, that draft became something more concrete: a filing with OMB, the White House office that reviews federal rules and policies with potentially significant economic effects before they can move forward. The filing itself gives no specifics on which peptides it covers or what conditions would apply. Two people familiar with the plan told the AP it is meant to let pharmacies temporarily compound popular peptides, with BPC-157 specifically named. HHS did not respond to the AP's request for comment.

OMB review is a required stop, not a rubber stamp. It can take anywhere from a few days to many months, and a filing can emerge changed, stalled indefinitely, or dropped altogether. Nothing about a pending OMB review tells the public what the final policy will say or when it might be announced; it only confirms that a specific document now exists inside the federal process, with a timestamp attached.

What "enforcement discretion" would and wouldn't change

The reason HHS is reportedly reaching for enforcement discretion rather than a formal rule traces back to a split vote at the FDA's Pharmacy Compounding Advisory Committee in July. That panel recommended six of seven peptides — including BPC-157, KPV, TB-500, MOTS-c, epitalon and semax — for the FDA's 503A Bulks List, the roster of substances pharmacies may legally compound. But adding something to that list through the normal channel means notice-and-comment rulemaking, which can run for years. Enforcement discretion skips that: the FDA would simply announce it isn't prioritizing enforcement against pharmacies that compound certain peptides, without changing anything about those peptides' underlying legal status. BPC-157 and more than a dozen other injectable peptides currently sit on an FDA list of substances considered too risky for compounding, over concerns the agency has cited including contamination, allergic reactions and tumor growth.

That distinction matters because a non-enforcement promise can be withdrawn as easily as it was given, and it does nothing to generate the clinical data the FDA's own career staff said was missing when they reviewed the evidence in July: a handful of small, short, uncontrolled human studies for BPC-157, and no human studies at all for several of the other six peptides.

The market is already pricing in an answer

A regulatory filing with no public text has still moved real money. Wall Street analysts cited by the AP estimate the affected peptide market could be worth $2 billion to $3 billion, and two telehealth companies, Hims & Hers and Noom, have each said they plan to offer peptides to customers if federal access eases. Online reaction split along predictably commercial lines: Brigham Buhler, who operates a wellness clinic and sells peptides through an online service, posted on social media that the filing was "huge" and framed the question as one of "medical freedom" rather than evidence. None of that reaction changes what is or isn't known about these compounds in human bodies; it is a market and a political coalition responding to a procedural step, which is a different thing from a safety finding.

What's known, and what still isn't

What's confirmed: a dated OMB filing exists, HHS Secretary Robert F. Kennedy Jr. has pushed to widen peptide access since taking office, and the FDA's July advisory panel voted non-bindingly to loosen restrictions on six of seven peptides against the recommendation of its own scientists. What isn't confirmed: which peptides beyond BPC-157 the policy would cover, what conditions (if any) would be attached, how long OMB review will take, or whether the formal 503A rulemaking process is still happening in parallel or has been shelved in favor of this shortcut. The AP's sourcing on the policy's contents remains two anonymous officials; no agency document describing the policy's substance has been made public.

What this means for researchers

Nothing about an OMB filing changes the legal or evidentiary status of any peptide today. If the policy is finalized as described, it would shift where certain compounds sit in a regulatory gray zone — from outright restricted to compoundable-by-prescription under a non-enforcement promise — without touching the underlying question the FDA's own staff raised in July: that the human safety and efficacy data most of these molecules have is thin, short-term, or entirely absent.

For researchers tracking the policy mechanics rather than the politics, the useful distinction is between a procedural filing and a finished rule. This is the former. The Journal will cover whatever OMB actually produces, if and when it becomes public, rather than the reported drafts and market reactions along the way. Readers who want background on the compounds named in this filing can find it on Torrey Labs' compound guide; what a pharmacy may eventually be permitted to compound and what has actually been established about a compound in humans remain two separate questions, and as of this week, only the first one moved.